Literature DB >> 25655003

IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway.

Xi-Xiang Yu1, Zhe Hu, Xian Shen, Li-Yang Dong, Wei-Zhong Zhou, Wen-Hao Hu.   

Abstract

BACKGROUND: As a pro-inflammatory cytokine, IL-33 has been demonstrated to play an important role in tumor progression. It is reported that IL-33 is highly expressed in the serum and tumor tissues of patients with gastric cancer. However, the function of IL-33 in gastric cancer remains elusive. We here tried to elucidate the effects of IL-33 on gastric cancer cell invasion and migration.
METHODS: Invasion assay and migration assay were performed to assess the effects of IL-33 on gastric cancer cell invasion and migration. ST2 receptor was silenced by siRNA, and ERK1/2 pathway was inhibited by U0126. Protein levels of MMP-3 and IL-6 in cell supernatant were measured by ELISA.
RESULTS: IL-33 promoted the invasion and migration of gastric cancer cells, in a dose-dependent manner. Knockdown of the IL-33 receptor ST2 attenuated the IL-33-mediated invasion and migration. Furthermore, via ST2 receptor, IL-33 induced the activation of ERK1/2 and increased the secretion of MMP-3 and IL-6. In addition, blockage of ERK1/2 pathway resulted in inhibition of invasion and migration induced by IL-33, and downregulation of MMP-3 and IL-6 production.
CONCLUSIONS: IL-33 promotes gastric cancer cell invasion and migration by stimulating the secretion of MMP-3 and IL-6 via ST2-ERK1/2 pathway. Thus, IL-33 may be a useful marker for the diagnosis and treatment of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25655003     DOI: 10.1007/s10620-014-3463-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  IL-33 mediates inflammatory responses in human lung tissue cells.

Authors:  Akiko Yagami; Kanami Orihara; Hideaki Morita; Kyoko Futamura; Noriko Hashimoto; Kenji Matsumoto; Hirohisa Saito; Akio Matsuda
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Involvement of ERK and p38 MAPK pathways on Interleukin-33-induced RANKL expression in osteoblastic cells.

Authors:  Yuichi Mine; Seicho Makihira; Yu Yamaguchi; Hideki Tanaka; Hiroki Nikawa
Journal:  Cell Biol Int       Date:  2014-01-31       Impact factor: 3.612

3.  Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion.

Authors:  Irina G Luzina; Edward M Pickering; Pavel Kopach; Phillip H Kang; Virginia Lockatell; Nevins W Todd; John C Papadimitriou; Andrew N J McKenzie; Sergei P Atamas
Journal:  J Immunol       Date:  2012-05-25       Impact factor: 5.422

4.  The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma.

Authors:  Su-Feng Chen; Shin Nieh; Shu-Wen Jao; Min-Zu Wu; Chia-Lin Liu; Yun-Ching Chang; Yaoh-Shiang Lin
Journal:  J Pathol       Date:  2013-08-12       Impact factor: 7.996

5.  Correlations between serum IL33 and tumor development: a meta-analysis.

Authors:  Xiang-Jun Chen; Ying-De Huang; Nian Li; Min Chen; Fang Liu; Dan Pu; Tao-You Zhou
Journal:  Asian Pac J Cancer Prev       Date:  2014

6.  Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden.

Authors:  Pietro Santulli; Marc Even; Sandrine Chouzenoux; Anne-Elodie Millischer; Bruno Borghese; Dominique de Ziegler; Frédéric Batteux; Charles Chapron
Journal:  Hum Reprod       Date:  2013-06-05       Impact factor: 6.918

7.  High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.

Authors:  Dominik Bergis; Valentin Kassis; Annika Ranglack; Verena Koeberle; Albrecht Piiper; Bernd Kronenberger; Stefan Zeuzem; Oliver Waidmann; Heinfried H Radeke
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

8.  Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping.

Authors:  S Tominaga; N A Jenkins; D J Gilbert; N G Copeland; T Tetsuka
Journal:  Biochim Biophys Acta       Date:  1991-08-27

9.  IL-33/ST2 axis in innate and acquired immunity to tumors.

Authors:  Ivan P Jovanovic; Nada N Pejnovic; Gordana D Radosavljevic; Nebojsa N Arsenijevic; Miodrag L Lukic
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

10.  Serum soluble ST2 is associated with ER-positive breast cancer.

Authors:  Da-Peng Lu; Xiang-Yu Zhou; Lu-Tian Yao; Cai-Gang Liu; Wei Ma; Feng Jin; Yun-Fei Wu
Journal:  BMC Cancer       Date:  2014-03-18       Impact factor: 4.430

View more
  38 in total

1.  IL-33 is associated with unfavorable postoperative survival of patients with clear-cell renal cell carcinoma.

Authors:  Zewei Wang; Le Xu; Yuan Chang; Lin Zhou; Hangcheng Fu; Weijuan Zhang; Yuanfeng Yang; Jiejie Xu
Journal:  Tumour Biol       Date:  2016-03-01

2.  Decreased ST2 expression is associated with gastric cancer progression and pathogenesis.

Authors:  Feihu Bai; Fangyun Ba; Yanjie You; Yaning Feng; Wei Tao; Chuanxia Wu; Mengna Jiu; Yongzhan Nie
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

3.  Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients.

Authors:  Wenwei Hu; Xiaodong Li; Qing Li; Yan Tan; Bin Xu; Quanqin Xie; Xu Deng; Binfeng Lu; Jingting Jiang; Changping Wu
Journal:  Pathol Oncol Res       Date:  2016-12-20       Impact factor: 3.201

4.  IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer.

Authors:  Yujiang Fang; Lei Zhao; Huaping Xiao; Kathryn M Cook; Qian Bai; Elizabeth J Herrick; Xuhui Chen; Chenglu Qin; Ziwen Zhu; Mark R Wakefield; Michael B Nicholl
Journal:  Med Oncol       Date:  2017-01-05       Impact factor: 3.064

5.  Novel interleukin-33 and its soluble ST2 receptor as potential serum biomarkers in parotid gland tumors.

Authors:  Pawel Sowa; Maciej Misiolek; Maciej Zielinski; Bogdan Mazur; Monika Adamczyk-Sowa
Journal:  Exp Biol Med (Maywood)       Date:  2018-05

6.  Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration.

Authors:  Ourania S Kotsiou; Rajesh M Jagirdar; Eleftherios D Papazoglou; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Inflammation       Date:  2019-12       Impact factor: 4.657

Review 7.  Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's Perspective.

Authors:  Tae Young Jang; Young Hyo Kim
Journal:  Int Neurourol J       Date:  2015-09-22       Impact factor: 2.835

Review 8.  Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation.

Authors:  Ari B Molofsky; Adam K Savage; Richard M Locksley
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

9.  Tristetraprolin inhibits gastric cancer progression through suppression of IL-33.

Authors:  Kaiyuan Deng; Hao Wang; Ting Shan; Yigang Chen; Hong Zhou; Qin Zhao; Jiazeng Xia
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

10.  Interleukin 33 Triggers Early Eosinophil-Dependent Events Leading to Metaplasia in a Chronic Model of Gastritis-Prone Mice.

Authors:  Carlo De Salvo; Luca Pastorelli; Christine P Petersen; Ludovica F Buttò; Kristine-Ann Buela; Sara Omenetti; Silviu A Locovei; Shuvra Ray; Hannah R Friedman; Jacob Duijser; Wei Xin; Abdullah Osme; Fabio Cominelli; Ganapati H Mahabeleshwar; Jason C Mills; James R Goldenring; Theresa T Pizarro
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.